title: Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man.
abstract: OBJECTIVE
  The present study examines the role of alpha 1-adrenoceptors in determining the renal haemodynamic and sodium excretory responses to a physiological dose of angiotensin II in man.
  
  
  METHODS
  The effects of a low-dose infusion of angiotensin II (1 ng/kg per min) and a non-depressor dose of prazosin (0.25 mg), alone and in combination, on urinary sodium excretion (UNaV), effective renal plasma flow (ERPF), glomerular filtration rate (GFR) and segmental tubular function were studied in eight normal male subjects.
  
  
  METHODS
  Subjects were studied undergoing maximal water diuresis. Clearances of inulin and para-aminohippurate were employed to estimate GFR and ERPF, respectively. Segmental tubular handling was assessed by both lithium clearance (CLi) and solute-free water methods.
  
  
  RESULTS
  Angiotensin II decreased UNaV without altering ERPF and GFR. Angiotensin II caused a significant fall in fractional CLi, which may indicate a proximal tubular effect of angiotensin II. Angiotensin II alone also increased fractional reabsorption of sodium delivered to the distal nephron, as evaluated by both the CLi method and by estimation of solute-free water clearance. When angiotensin II was given in combination with prazosin, which on its own had no apparent effects on any renal parameters, the antinatriuretic and tubular effects of angiotensin II were significantly blunted.
  
  
  CONCLUSIONS
  These findings suggest that low doses of circulating angiotensin II are able to modulate UNaV by increasing sodium reabsorption in the proximal and, to some extent, the distal nephron segment in man. The study also showed that a non-depressor dose of prazosin blunted the renal effects of angiotensin II, thereby providing tentative evidence of a renal interaction between alpha-adrenoceptors and angiotensin II in man.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, UK.
authors.forename: C C
authors.initials: CC
authors.lastname: Lang
authors.forename: A R
authors.initials: AR
authors.lastname: Rahman
authors.forename: D J
authors.initials: DJ
authors.lastname: Balfour
authors.forename: A D
authors.initials: AD
authors.lastname: Struthers
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000502:physiology*; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects / Q000502:physiology; D008297:Male; D009318:Natriuresis / Q000187:drug effects / Q000502:physiology*; D011224:Prazosin / Q000494:pharmacology*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D012079:Renal Circulation / Q000187:drug effects / Q000502:physiology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology
chemical_list: D011942:Receptors, Adrenergic, alpha; D000804:Angiotensin II; D011224:Prazosin